{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007474","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.338726+00:00","generated_at":"2026-06-02T06:48:17.753430+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Virios Therapeutics Q1 net loss $1.3M; Long-COVID study enrollment >50%","bullets":["Net loss $1.3M ($0.07/shr) vs $1.5M ($0.08/shr) in Q1 2023; cash $2.4M at March 31, 2024.","R&D expenses $0.3M (down from $0.5M); G&A expenses $1.0M (down from $1.1M).","BHC Long-COVID phase 2 trial (IMC-2) exceeded 50% enrollment; top-line data expected H2 2024.","Preliminary safety shows IMC-2 well tolerated; no serious adverse events reported to date.","Global patent for IMC-2 covering Long-COVID and Alzheimer's published; FM partner discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007474","json":"https://secwatch.observer/filing/0001558370-24-007474.json","markdown":"https://secwatch.observer/filing/0001558370-24-007474.md","text":"https://secwatch.observer/filing/0001558370-24-007474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/0001558370-24-007474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/viri-20240509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:48:17.753430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2786f375d1665b39cffcdb74d1ec2e57a24beb8","claim":"Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $1.3 million, EPS $0.07 basic and diluted net loss per share.","evidence_excerpt":"Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/0001558370-24-007474-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$1.3 million"},{"label":"EPS","value":"$0.07 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}